COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Rush University Medical Center

S. Jain

New European Guidelines on Pulmonary Embolism: What Has Changed and …

PERT Consortium 2021

S. Konstantinides

VTE Prophylaxis After THA for Asian Population: Pharmacological Prop…

Arthroplasty Society in Asia

M. Mihara

VTE Prophylaxis After THA: Chinese Experience

Arthroplasty Society in Asia

H. Cai

Bleeding Management and Use of Anticoagulants: Panel Discussion

PERT Consortium 2021

G. Piazza, M. McDaniel, M. Huisman, D. Siegal, C. Pollack

VTE Prophylaxis After THA in the Asians: Messages from 2019 AP VTE C…

Arthroplasty Society in Asia

A. Tanavalee

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Five Things Every Internist Should Know About Anticoagulants

McMaster University Department of Medicine

S. Mithoowani

Cancer-Associated Thrombosis: Defining, Risk Assessment, and Prognos…

BMFcases

T. Bat, M. Carrier

Acute DVT: When to and When Not to Intervene?

Venous Edge

S. Elias, C. Pena, C. Huff, R. Winokur, K. BROWN

Pulmonary Embolism During Pregnancy

Pulmonary Embolism 2016

J. Bartholomew

TCT 2022: Why Intervene on Submassive Pulmonary Embolism Patients?

TCT 2022 Conference Coverage

W. Jaber

Extended Anticoagulation for VTE

Jeffrey Weitz

Prevention and Treatment of Cancer-Associated Thrombosis: What Are t…

James Douketis

Cancer-Associated Thrombosis: Anticoagulant Dose and Duration Consid…

BMFcases

T. Bat, M. Carrier

Pulmonary Embolism: Where Are We in 2024?

UPMC

B. Rivera-Lebron

Long Term Anticoagulation - How and For How Long?

Pulmonary Embolism Symposium (PERT 2017)

Catheter-Based Interventions for Acute Pulmonary Embolism: What Are …

Mount Sinai Endovascular Fellows Course

J. Giri

Update on HI-PEITHO - A Landmark Clinical Trial in PE

PERT Consortium 2022

K. Rosenfield